Skip to content
naulon
Get started
Not checkedNot checked for notices yet.

Systemic treatment for hepatocellular carcinoma

Manushi Aggarwal, Abeer Arain, Zhaohui Jin

Chronic Diseases and Translational Medicine · 2018

doi:10.1016/j.cdtm.2018.08.003 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new promising therapeutic options for these patients. This review article summarizes systemic treatment options evaluated in HCC focusing on the most recently published data and ongoing studies.

Abstract licence: CC BY-NC-ND

References53

  1. 17.

    Management of Hepatocellular Carcinoma: An Update Δσ · 2011

  2. 30.

    The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level · 2017

38 more references, whose wording the paper’s licence keeps private.

All 53 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.